| abstract |
The present invention binds to a region comprising LNR3 of PAPP-P, in one embodiment, effectively inhibits proteolysis of IGFBP-4 and does not interact with PAPP-A exosite (s) such as antibodies that are not for IGFBP-5. It's about characters. This region comprising LNR3 represents a substrate binding exosite that can target selective proteolytic inhibition. Accordingly, the present invention relates in one embodiment to differential inhibition of natural protease substrates by targeting exosites. |